Klin Onkol 2014; 27(Suppl 1): 110-115. DOI: 10.14735/amko20141S110.
Summary
Development of novel diagnostic and therapeutic approaches in cancer research requires sensitive and quantitative assays for determination of cancer-associated proteins in clinical samples. Novel quantitative targeted proteomic approaches are overviewed in this communication. A major advantage of selected reaction monitoring (SRM) and pseudo- SRM lies in the selective and sensitive quantification of selected proteins in large sample sets. As such, they represent an alternative to immunochemical approaches. On the other hand, the potential of HRM and SWATH lies in recording of digital fingerprints, which enable post-acquisition quantitative proteomic data mining on a similar basis to SRM. This article shows applications of targeted proteomics in a number of cancer research studies where they were used for quantification and validation of current or potential protein biomarkers and to study their role in cancer development and progression.
